SCHEMBL6003700

SCHEMBL6003700

O=C(O)C(Cc1ccc(Cl)c(Cl)c1)c1cccs1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
KMT2A Q03164 2/20 0.45
HSP90AA1 P07900 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 4/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.42
PTPRC P08575 2/20 0.41
PTPRG P23470 1/20 0.41
PTPN1 P18031 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
TP53 P04637 1/20 0.41
FPR2 P25090 1/20 0.40
POLB P06746 1/20 0.40
CYP2C19 P33261 1/20 0.40
PNMT P11086 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006143 1.00 LMNA (0.45) LMNAKMT2AHSP90AA1L3MBTL1MAPT
SCHEMBL9108692 0.82 POLB (0.44) LMNAKMT2AMAPTMEN1ALDH1A1
SCHEMBL27878871 0.81 POLB (0.50) MAPTNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL9107951 0.78 TP53 (0.46) LMNAKMT2AMEN1NPC1ALDH1A1
SCHEMBL6003758 0.78 FPR2 (0.51) KMT2AMEN1PTPRGPTPN1PPARG
SCHEMBL6005718 0.78 FPR2 (0.51) KMT2AMEN1PTPRGPTPN1PPARG
SCHEMBL6005310 0.78 FPR2 (0.51) KMT2AMEN1PTPRGPTPN1PPARG
SCHEMBL6177780 0.75 LDHA (0.56) LMNAKMT2AL3MBTL1MEN1NPC1
SCHEMBL6005468 0.75 PPARG (0.43) MAPTPTPRCPTPRGPTPN1PPARG
SCHEMBL6005083 0.75 PPARG (0.43) MAPTPTPRCPTPRGPTPN1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP LMNA 1324/4885KMT2A 3113/4885HSP90AA1 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.